NVIDIA CLARA DISCOVERY

Accelerated Computational Drug Discovery

Built to support cross-disciplinary workflows, NVIDIA Clara™  Discovery combines the power of accelerated computing, AI, and machine learning to supercharge the entire drug development process, unlocking the potential to bring life-saving drugs to market faster.

GPU-Powered Drug Discovery

Clara Discovery is a collection of frameworks, applications, and AI models

Apply AI and HPC to Drug Research

Clara Discovery is a collection of frameworks, applications, and AI models enabling GPU-accelerated drug discovery, with support for research in genomics, proteomics, microscopy, virtual screening, computational chemistry, visualization, clinical imaging, and natural language processing (NLP). Browse these tools in the NGC™ catalog, NVIDIA’s hub for GPU-optimized software.

Power Data-Driven Pharma R&D

Clara Discovery is optimized to run on NVIDIA DGX™ A100, the world’s most advanced AI system delivering five petaFLOPS of performance. Purpose-built for all accelerated computing workloads at scale, DGX A100 provides researchers the fastest time to solution and IT a unified, easy-to-deploy infrastructure to support the next-generation of drug discovery.

 View HPC Application Performance

 View Deep Learning Framework Performance

Full Stack Acceleration

Clara Discovery Partners

Schrodinger
Structura Biotechnology Inc
Vyasa

News

NVIDIA will build the UK’s most powerful Supercomputer to support healthcare researchers from universities to startups to research institutions.

A Dedication to Healthcare Research

Going online in late 2020, NVIDIA will build the UK’s most powerful supercomputer using NVIDIA DGX SuperPOD™ to support the entire ecosystem of cross-industry healthcare researchers from universities to startups to research institutions.

In partnership with GSK, NVIDIA will build a first  pharmaceutical AI lab combining Genetic and Clinical data

GSK AI-Powered Drug Discovery Lab to Deliver Therapies Faster

To accelerate drug and vaccine discoveries, GSK and NVIDIA are partnering together on an AI-powered lab that will unlock genetic and clinical data with increased precision and scale.

Pharma’s MELLODDY Consortium Joins Forces with NVIDIA to Supercharge AI Drug Discovery

Pharma’s MELLODDY Consortium Joins Forces with NVIDIA

Bringing together 17 partners, including 10 leading pharmaceutical companies, MELLODDY will use federated learning techniques and NVIDIA GPUs to leverage the world’s largest collaborative drug compound dataset for AI training without sacrificing data privacy.

Sign up for the latest healthcare news from NVIDIA